Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 14:7:33-39.
doi: 10.33393/grhta.2020.2139. eCollection 2020 Jan-Dec.

L’impatto della cross-copertura di dupilumab sulla spesa a carico del Servizio Sanitario Nazionale

[Article in Italian]
Claudio Jommi  1 , Filippo Cipriani  2 , Francesca Fanelli  2 , Maria P Pedone  2 , Walter Canonica  3
Affiliations

L’impatto della cross-copertura di dupilumab sulla spesa a carico del Servizio Sanitario Nazionale

[Article in Italian]
Claudio Jommi et al. Glob Reg Health Technol Assess. .

Abstract

Background and research question:: Label extension for treatments and the relevant disease cross-coverage may produce an economic benefit. This paper assesses this benefit for dupilumab in the perspective of the Italian National Health Service. Dupilumab was approved for reimbursement for severe atopic dermatitis (AD), severe and refractory asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The analysis focused on the crowding-out effect of dupilumab on alternative treatments.

Methods:: The research relied on a simplified budget impact model. The model was populated by data from published evidence and relied on three alternative scenarios for market penetration (15%-30%-100%).

Results:: Avoidable direct health annual costs due to cross-coverage for (i) asthma in patients treated for AD ranged from 0.46 to 3.43 million euros, (ii) asthma in patients treated for CRSwNP ranged from 0.08 to 0.88 million euros, (iii) CRSwNP in patients treated for asthma ranged from 0.41 to 4.05 million euros respectively. The total economic benefit ranges from 0.95 to 8.36 million euros.

Discussion:: The research estimated the crowding-out effect of dupilumab on alternative treatments. It did not incorporate avoided/incremental events due to a possible better/worse risk-benefit profile of dupilumab vs alternative treatments and the economic benefit of cross-coverage on lower diseases severity (for example mild asthma). Nonetheless, the analysis relies on the best available evidence for Italy to shed light on a topic which has not been sufficiently investigated, and provides data that will be potentially very important for policy-makers, payers and those who manage new treatments.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: CJ and WC have received fees from Sanofi for the participation in Advisory Boards and Conferences.

References

    1. Campillo-Artero C, Puig-Junoy J, Segú-Tolsa JL, Trapero-Bertran M. Price Models for Multi-indication Drugs: A Systematic Review. Appl Health Econ Health Policy. 2020;18(1):47–56. - PubMed
    1. Jommi C, Minghetti P. In: Pharmaceutical Prices in the 21st Century 2015. Zaheer-Ud-Din Babar., editor. Springer,; London:: Pharmaceutical Pricing Policies in Italy, pp. 131–51.
    1. [ultima data di accesso 13/3/2020]; www.quotidianosanita.it/scienza-e-farmaci/articolo.php?articolo_id=64124
    1. de Bruin-Weller M, Thaçi D, Smith CH et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial. J Dermatol. 2018;178(5):1083–101. (CAFÉ) - PubMed
    1. Blauvelt A, de Bruin-Weller M, Gooderham M et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids: a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–303. (CHRONOS) - PubMed

LinkOut - more resources